Efficacy and Safety of a Purified Standardised Wasp Venom Preparation

This study is ongoing, but not recruiting participants.

Sponsored by:	Allergopharma Joachim Ganzer KG
Information provided by:	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00263926

Purpose

The trial is performed to assess efficacy and safety of a purified standardised wasp venom preparation in wasp venom allergy

Condition	Intervention	Phase
Allergy	Biological: wasp venom	Phase III

MedlinePlus related topics: Allergy

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Immunotherapy of Wasp Venom Allergy: Comparison of a Purified Preparation to Conventional Aqueous Wasp Venom in an Open Controlled Study

Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date:	March 2001
Estimated Study Completion Date:	May 2007

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263926

Locations

Germany
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465

Sponsors and Collaborators

Allergopharma Joachim Ganzer KG

Investigators

Principal Investigator:

Annemie Narkus, M.D.

unaffiliated

More Information

Leader in specific allergy research and therapy This link exits the ClinicalTrials.gov site

Study ID Numbers:	Al1000ig
Study First Received:	December 9, 2005
Last Updated:	July 16, 2008
ClinicalTrials.gov Identifier:	NCT00263926
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:

Wasp venom allergy,
specific immunotherapy

Study placed in the following topic categories:

Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009